# Conotoxins: Complete Research Profile — Cone Snail Venom Peptides as Precision Ion Channel Pharmacology Tools (2026)
> Research Use Only (RUO). All content on this page describes peptide reagents intended exclusively for laboratory research. These compounds are not approved for use in humans or animals and are not intended for diagnostic, therapeutic, or veterinary applications.
---
What Are Conotoxins?
Conotoxins are a structurally diverse superfamily of small, disulfide-rich peptides produced in the venom ducts of predatory marine cone snails (genus Conus). With roughly 700–1000 extant Conus species — each maintaining a venom arsenal of 50–200 unique peptides — the conotoxin chemical space encompasses an estimated 100,000 or more distinct sequences, the vast majority still uncharacterized.
For ion channel pharmacologists and neuroscientists, conotoxins represent arguably the richest and most selective library of small-molecule-sized probes in existence. Individual compounds block voltage-gated calcium, sodium, and potassium channels with nanomolar to picomolar affinity; others antagonize nicotinic acetylcholine receptors with extraordinary subtype discrimination; still others target NMDA receptors, noradrenaline transporters, and neurotensin receptors. This exquisite selectivity reflects 50–100 million years of evolutionary pressure: cone snails must immobilize prey (fish, worms, mollusks) in milliseconds, and any toxin that cross-reacts with the predator's own channels is a lethal liability.
The result is a collection of research reagents that grants investigators tools unavailable from any synthetic chemistry program — ultra-selective pharmacological scissors capable of turning off one ion channel subtype while leaving its closest relatives untouched.
---
Biological Origins: *Conus* and the Venom Apparatus
Conus snails are gastropod mollusks found primarily in tropical and subtropical reef environments. Their venom system comprises a pair of venom ducts, a muscular venom bulb, and a harpoon-like hollow tooth (the radula) ejected through a long, extensible proboscis. Prey envenomation triggers rapid, multi-toxin neuromuscular blockade.
Each Conus species expresses a highly species-specific venom profile. The piscivorous (fish-hunting) species — Conus geographus, Conus magus, Conus striatus — tend to produce the most pharmacologically potent conotoxins relevant to vertebrate ion channels, because their evolutionary target is a vertebrate nervous system. The molluscivorous and vermivorous species target invertebrate receptors and provide complementary tools for comparative pharmacology.
Venom Complexity and Conopeptide Nomenclature
The standard nomenclature assigns each conotoxin a Greek letter prefix indicating its pharmacological family (α, μ, ω, δ, κ, etc.), followed by the species code. For example:
- •ω-conotoxin MVIIA — omega family, from Conus magus, peptide VII-A
- •α-conotoxin ImI — alpha family, from Conus imperialis, peptide I
- •μ-conotoxin GIIIA — mu family, from Conus geographus, peptide III-A
---
Structural Features: Disulfide Frameworks and Gene Superfamilies
Conotoxins range from ~7 to ~70 amino acids in length, with most pharmacologically useful research tools in the 10–35 residue range. The defining structural feature is a disulfide bond framework generated from multiple cysteine pairs. These disulfide bridges produce compact, thermally stable scaffolds that resist proteolytic degradation — a significant practical advantage as research reagents.
Cysteine Framework Classification
Researchers classify conotoxins by their cysteine arrangement using a roman numeral framework system:
| Framework | Cysteine Pattern | Pharmacological Class |
|---|---|---|
| I | CC–C–C | α-conotoxins (nAChR) |
| II | CCC–C–CC | δ, μ, ι-conotoxins |
| III | CC–C–C–CC | — |
| VI/VII | C–C–CC–C–C | ω-conotoxins (CaV), μ-conotoxins |
| XIV | C–C | conantokins (NMDAR) |
Gene Superfamilies
At the genomic level, conotoxin precursors are sorted into ~16 gene superfamilies (A, M, O1, O2, O3, T, S, etc.) based on conserved N-terminal signal sequences. The O superfamily encodes the ω-conotoxins; the A superfamily encodes the α-conotoxins. This classification system, curated in the ConoServer database (>8,000 protein sequences, >200 structures), enables bioinformatic prediction of function from sequence alone — an increasingly powerful tool as transcriptomic venomics expands the known conotoxin sequence space.
---
Pharmacological Classification: Major Research-Relevant Families
α-Conotoxins — Nicotinic Acetylcholine Receptor Probes
α-Conotoxins are competitive antagonists of nicotinic acetylcholine receptors (nAChRs), a family of pentameric ligand-gated ion channels expressed throughout the nervous system, neuromuscular junction, and immune cells. Their value as research tools derives from their ability to discriminate nAChR subtypes that differ only in subunit composition — a distinction that is pharmacologically intractable with classical small-molecule antagonists like mecamylamine or hexamethonium.
α-Conotoxin ImI (from Conus imperialis): A compact 12-residue peptide with CC/CC (framework I) disulfide bonds that preferentially blocks homomeric α7 nAChRs at nanomolar concentrations, with >100-fold selectivity over muscle-type (α1β1γδ) receptors. ImI and its close relative ImII bind distinct sites on the α7 receptor despite differing by only three residues, making the pair useful for epitope mapping of the α7 orthosteric binding interface [PMID: 7651351; PMID: 15609996].
α-Conotoxin MII (from Conus magus): A 16-residue peptide that potently blocks α3β2-containing nAChRs and, through careful use of analogs, α6-containing subtypes. Its high selectivity for α3β2 over α4β2 has made it a standard tool for dissecting dopaminergic striatal circuits, where α3β2 nAChRs modulate dopamine release. Autoradiographic ligand binding with [¹²⁵I]-α-conotoxin MII identified a distinct nAChR population in mouse brain regions [PMID: 10779374]. Subsequent analog work demonstrated selectivity for α6-containing subtypes, expanding its utility in addiction and reward circuitry research [PMID: 15044624].
Other α-conotoxins: GI and GIA (α1 neuromuscular blockers from C. geographus), PnIA/PnIB (α3β2/α3β4 discriminators from C. pennaceus), and Vc1.1 and RgIA (α9α10 blockers) represent additional subtype-selective probes for pain, autonomic, and sensory research contexts.
ω-Conotoxins — Voltage-Gated Calcium Channel Blockers
ω-Conotoxins target voltage-gated calcium channels (VGCCs), specifically the CaV2.x subfamily that mediates neurotransmitter release at central and peripheral synapses. They act as pore blockers, physically occluding the channel mouth with slow-off kinetics that can produce near-irreversible blockade under standard patch-clamp conditions — valuable for establishing a clean calcium channel null baseline in ex vivo preparations.
ω-Conotoxin GVIA (from Conus geographus): The definitive selective blocker of N-type (CaV2.2) channels. GVIA has been used for over three decades to distinguish N-type from L-type (dihydropyridine-sensitive) and P/Q-type (ω-agatoxin IVA-sensitive) calcium currents in neurons. Its high affinity (Kd ~1–5 nM) and extremely slow off-rate make it the gold standard for N-type calcium channel inactivation assays. Structure-activity relationship studies established that basic residues at positions 10 (Arg), 17 (Lys), and 19 (Arg) are critical for channel binding [PMID: 8394704].
ω-Conotoxin MVIIA (from Conus magus): A 25-residue peptide sharing the same CaV2.2 selectivity profile as GVIA but with slightly different binding kinetics, MVIIA is the precursor to ziconotide (Prialt®), the first conotoxin-derived compound to receive FDA approval (2004). Its synthetic equivalent has been extensively characterized in structural biology: the cryo-EM structure of human CaV2.2 bound to ziconotide was solved at 3.0 Å, revealing a pore-blocking mechanism involving insertion into the extracellular vestibule with contacts across all four voltage sensor domains [PMID: 34234349]. MVIIA/ziconotide remains a critical positive control for CaV2.2 pharmacological assays. Reviews of its structure-activity relationship in the context of analgesic drug discovery are available [PMID: 9792182].
ω-Conotoxin CVID (from Conus catus): CVID also blocks CaV2.2 with high selectivity, but has more reversible binding kinetics than GVIA, making it useful for concentration-response studies where a washable blocker is required.
μ-Conotoxins — Voltage-Gated Sodium Channel Blockers
μ-Conotoxins target voltage-gated sodium channels (NaV1.x), particularly the muscle isoform NaV1.4 and several neuronal isoforms. Their mechanism parallels tetrodotoxin (TTX): pore blockade via occlusion of the selectivity filter. Unlike TTX, however, individual μ-conotoxins show isoform selectivity that makes them valuable for dissecting which NaV subtypes carry a given physiological current.
μ-GIIIA, GIIIB, GIIIC (from C. geographus): Classic muscle NaV1.4 blockers used to separate muscle action potentials from neuronal ones in mixed culture preparations. GIIIA is also used to probe the outer vestibule geometry of NaV1.4.
SmIIIA, PIIIA, and SxIIIA: Neuronal-isoform-preferring μ-conotoxins useful for dissecting NaV1.1–NaV1.3 and NaV1.6 contributions to action potential firing in CNS neurons. Their availability as synthetic reagents has enabled detailed subtype-selectivity profiling across the NaV1 family.
δ-Conotoxins — NaV Inactivation Inhibitors
Where μ-conotoxins block NaV channels, δ-conotoxins inhibit fast inactivation, causing prolonged sodium channel opening and repetitive firing. They bind to receptor site 6 on the channel, a distinct pharmacophore from pore-blocking toxins. δ-TxVIA (from Conus textile) and δ-EVIA are used to study the mechanism of fast inactivation and the functional role of sustained sodium conductance in neuronal excitability research.
κ-Conotoxins — Potassium Channel Probes
κ-Conotoxins (e.g., κM-RIIIJ from Conus radiatus) block voltage-gated potassium channels, particularly Kv1.x subtypes. While less numerous than the α and ω families, κ-conotoxins provide complementary pharmacological tools alongside scorpion toxins (charybdotoxin, agitoxins) and dendrotoxins for KV channel characterization.
Conantokins — NMDA Receptor Subunit-Selective Antagonists
Conantokins are a structurally distinct conotoxin subfamily lacking disulfide bonds. Instead, they contain multiple γ-carboxyglutamate (Gla) residues that coordinate divalent cations and stabilize helical structure. Conantokin-G (Con-G, from Conus geographus) and conantokin-T (Con-T, from Conus tulipa) are competitive antagonists of NMDA receptors (NMDARs) with selectivity for NR2B- and NR2D-containing heteromers, respectively. Con-G is used as a selective NR2B subunit probe in studies of synaptic plasticity, long-term potentiation, and excitotoxicity.
---
Spotlight: Key Conotoxin Research Reagents
ω-Conotoxin GVIA
| Property | Value |
|---|---|
| Source | Conus geographus |
| Sequence | CKSOGSSCSTSYNSCCRRSNSNK (27 aa, 3 disulfides) |
| Primary target | CaV2.2 (N-type VGCC) |
| Secondary targets | CaV2.3 (weak) |
| Affinity (CaV2.2) | Kd ~1–5 nM |
| Off-rate | Very slow (quasi-irreversible) |
| Key application | Definitive N-type calcium current subtraction in neurons |
ω-Conotoxin MVIIA / Ziconotide
| Property | Value |
|---|---|
| Source | Conus magus |
| Sequence | CKGKGAKCSRLMYDCCTGSCRSGKC (25 aa, 3 disulfides) |
| Primary target | CaV2.2 (N-type VGCC) |
| Affinity (CaV2.2) | Kd ~0.1–1 nM |
| Crystal structure | PDB: 1OMG (NMR); CaV2.2 complex cryo-EM: 7MIY |
| Research application | N-type channel pharmacology positive control; structural pharmacology template |
α-Conotoxin ImI
| Property | Value |
|---|---|
| Source | Conus imperialis |
| Sequence | GCCSDPRCAWRC (12 aa, 2 disulfides) |
| Primary target | α7 nAChR |
| Selectivity | >100-fold over α3β2, α4β2 |
| Key application | α7 receptor functional studies; epitope mapping |
α-Conotoxin MII
| Property | Value |
|---|---|
| Source | Conus magus |
| Sequence | GCCSNPVCHLEHSNLC (16 aa, 2 disulfides) |
| Primary target | α3β2 nAChR |
| Selectivity for α6 | Achieved with peptide analogs |
| Key application | Striatal dopaminergic circuit mapping; addiction biology |
---
Database Resources for Conotoxin Research
ConoServer (conoserver.org) is the primary curated database for conopeptide sequences and structures. As of 2025, ConoServer contains over 8,100 protein sequences, nearly 3,000 nucleic acid entries, and 222 solved structures. The database classifies entries by gene superfamily, cysteine framework, and pharmacological target, providing a searchable resource for identifying research reagents with desired selectivity profiles.
UniProt / SwissProt maintains curated entries for well-characterized conotoxins with links to primary literature, functional data, and structural resources.
ConoDictor and ConoPrec are bioinformatics tools for classifying novel conotoxin sequences identified in venom gland transcriptomes. As venomics approaches expand the known sequence space, these tools provide rapid target prediction from sequence alone.
---
Laboratory Applications of Conotoxin Research Reagents
Voltage-Clamp Electrophysiology: Channel Subtype Dissection
The most common application of conotoxins in laboratory research is subtractive pharmacology — using toxins as pharmacological tools to assign specific ion currents to defined channel subtypes in native cells or expression systems.
A standard protocol for CaV current dissection in sympathetic neurons illustrates the approach:
1. Block L-type (CaV1.x) with 1–10 μM nifedipine
2. Subtract the remaining current by adding 1 μM ω-conotoxin GVIA → this fraction is N-type (CaV2.2)
3. The residual current after both blockers represents P/Q-type (CaV2.1) and R-type (CaV2.3)
This pharmacological dissection protocol has been a cornerstone of calcium channel neurobiology for three decades.
For sodium channel subtyping, μ-conotoxins are combined with TTX sensitivity profiling:
- •TTX-sensitive + μ-conotoxin-blocked currents → NaV1.4 (muscle), NaV1.1–1.3, NaV1.6
- •TTX-resistant currents → NaV1.5, NaV1.8, NaV1.9 (μ-conotoxin-insensitive)
Calcium Imaging and Fluorescence Assays
ω-Conotoxins are used as negative controls in calcium imaging experiments to establish the fraction of calcium transient attributable to N-type channels. Fluorescent derivatives (FITC-ω-conotoxin GVIA, biotin-MVIIA) are employed for receptor distribution mapping via immunofluorescence.
Binding Assays for CaV2.2 and nAChR Characterization
Radioiodinated [¹²⁵I]-ω-conotoxin GVIA and [¹²⁵I]-α-conotoxin MII are established radioligands for autoradiographic mapping of CaV2.2 and α3β2/α6 nAChR distributions in brain slice preparations. These assays have provided fundamental data on regional CaV2.2 expression and the neuroanatomical distribution of dopaminergic nAChRs [PMID: 10779374].
FRET and SPR Structural Pharmacology
Conotoxins serve as structural templates for biophysical studies. Their small size, well-defined disulfide scaffolds, and single pharmacological targets make them ideal for surface plasmon resonance (SPR) binding kinetics measurements and fluorescence resonance energy transfer (FRET)-based conformational assays. The solved cryo-EM structure of CaV2.2-ziconotide [PMID: 34234349] has become a reference framework for structure-based design of N-type calcium channel modulators.
Pain Pathway Research
N-type calcium channels play a pivotal role at the first synapse of the pain pathway — the connection between dorsal root ganglion (DRG) nociceptors and dorsal horn projection neurons in the spinal cord. ω-Conotoxins, particularly MVIIA/ziconotide, have served as definitive research tools demonstrating that selective CaV2.2 blockade suppresses neurotransmitter (glutamate, substance P) release from central DRG terminals, providing mechanistic validation of N-type calcium channel targeting as a strategy for nociception research [PMID: 15578997].
---
Stability, Handling, and Storage Considerations
Conotoxins are generally more stable than linear peptides due to their disulfide-braced compact structure, but proper handling remains important for maintaining research-quality reagents.
Reconstitution: Most conotoxins dissolve well in aqueous buffers (PBS, ACSF, physiological saline) at pH 7.0–7.4. Acidic conditions (pH < 4) may disrupt disulfide bonds over time. For ω-conotoxin GVIA and MVIIA, stock concentrations of 100–500 μM in aqueous buffer are stable for months at −20 °C.
Avoid thiol-reducing agents: DTT, β-mercaptoethanol, and TCEP cleave the disulfide bonds critical for biological activity. Standard patch clamp intracellular solutions must be checked for reducing agent content before use.
Freezing and thawing: Single-use aliquots are recommended. Repeated freeze-thaw cycles increase aggregation risk, particularly for the larger ω-conotoxins.
Adsorption: At very low concentrations (<10 nM) in polypropylene or glass vials, surface adsorption can reduce effective concentration. Addition of 0.1% BSA to the vehicle reduces nonspecific binding to container walls in dilute working solutions.
Working concentrations:
- •ω-GVIA for N-type blockade: 0.3–3 μM (irreversible; validate extent of blockade empirically)
- •ω-MVIIA for reversible N-type studies: 0.1–1 μM
- •α-ImI for α7 nAChR inhibition: 100 nM – 10 μM
- •α-MII for α3β2 inhibition: 1–100 nM
---
Conotoxins vs. Other Ion Channel Research Toxins
Researchers studying ion channels have access to several toxin families. Understanding when to choose conotoxins over alternatives is key to experimental design:
| Toxin Class | Source | Target | Selectivity Profile |
|---|---|---|---|
| ω-Conotoxins | Cone snail venom | N-type CaV2.2 | High (N vs. L and P/Q) |
| ω-Agatoxin IVA | Spider venom | P/Q-type CaV2.1 | High |
| Nifedipine | Synthetic DHP | L-type CaV1.x | Moderate |
| μ-Conotoxins | Cone snail venom | NaV subtypes | Isoform-selective |
| Tetrodotoxin (TTX) | Puffer fish | NaV (not NaV1.5/1.8/1.9) | Limited subtype discrimination |
| α-Conotoxins | Cone snail venom | nAChR subtypes | Exquisite subtype selectivity |
| α-Bungarotoxin | Krait venom | α7, α1 neuromuscular nAChR | Broad |
| Charybdotoxin | Scorpion venom | KV1/BK channels | Limited |
| Agitoxin-2 | Scorpion venom | KV1.1–1.3 | High for KV1 |
The key advantage of conotoxins over snake or scorpion toxins is subtype discrimination within a single channel family. For example, α-bungarotoxin blocks both α7 and neuromuscular α1 nAChRs, while α-conotoxin ImI cleanly spares muscle-type receptors.
---
Emerging Research: Synthetic and Engineered Conotoxins
Advances in solid-phase peptide synthesis (SPPS) have made synthetic conotoxins widely accessible, eliminating dependence on venomous animals and enabling systematic structure-activity relationship (SAR) studies. Key developments include:
Regioselective disulfide formation: Orthogonal protecting group strategies (Acm/tBu, Trt/Acm) allow directed disulfide bond formation between defined cysteine pairs, ensuring the correct native fold is obtained rather than a mixture of disulfide isomers.
Conotoxin mimetics: Academic and pharmaceutical groups have designed small-molecule and constrained peptide mimetics of ω-conotoxin GVIA targeting the same CaV2.2 binding interface. These efforts are informed by the structural pharmacology of natural conotoxins and aim to address the pharmacokinetic limitations of peptide tools in more complex research settings.
Deep mutational scanning: Synthetic chemistry enables systematic residue-by-residue alanine scanning of conotoxins to map pharmacophore elements with high resolution. This approach has been applied to ω-GVIA (mapping basic residue contributions to channel binding [PMID: 8394704]) and α-conotoxins (identifying key pharmacophore residues for nAChR subtype discrimination).
Transcriptomic venomics: Next-generation sequencing of Conus venom gland transcriptomes continues to uncover novel conotoxin sequences at a rate far exceeding biochemical characterization. Bioinformatic prediction tools combined with chemical synthesis are bridging this gap, enabling rapid hypothesis-driven profiling of novel sequences.
---
Research Applications Summary
| Research Area | Recommended Conotoxin | Purpose |
|---|---|---|
| CaV2.2 pharmacology | ω-GVIA, ω-MVIIA | N-type channel blockade, current subtraction |
| α7 nAChR biology | α-ImI, α-ImII | Selective α7 blockade, epitope mapping |
| α3β2 / α6 nAChR | α-MII, MII analogs | Dopamine circuit mapping, addiction research |
| NaV1.4 neuromuscular | μ-GIIIA, GIIIB | Muscle sodium channel blockade |
| NMDAR NR2B biology | Conantokin-G | Selective NR2B antagonism |
| NaV inactivation | δ-EVIA, δ-TxVIA | Inactivation mechanism studies |
| KV1.x channels | κM-RIIIJ | Potassium channel subtype dissection |
| Pain pathway research | ω-MVIIA | CaV2.2-mediated nociceptor neurotransmission |
---
Key References
1. Lewis RJ, Garcia ML. Therapeutic potential of venom peptides. Nat Rev Drug Discov. 2003;2(10):790-802. [PMID: 14526382]
2. Olivera BM, Cruz LJ. Conotoxins, in retrospect. Toxicon. 2001;39(1):7-14. [PMID: 11137668]
3. Mcintosh JM, et al. alpha-conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade. J Neurosci. 1994;14(11 Pt 2):6942-6950. [PMID: 7651351]
4. Whiteaker P, et al. 125I-alpha-conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain. Mol Pharmacol. 2000;57(5):913-925. [PMID: 10779374]
5. Loughnan M, et al. alpha-conotoxins ImI and ImII target distinct regions of the human alpha7 nicotinic acetylcholine receptor and distinguish human nicotinic receptor subtypes. J Biol Chem. 2004;279(44):45480-45491. [PMID: 15609996]
6. Elmslie KS. Calcium channel blockers in the treatment of disease. J Neurosci Res. 2004;75(6):733-741. [PMID: 14994334]
7. Bowersox SS, et al. Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker. J Pharmacol Exp Ther. 1998;289(3):1243-1249. [PMID: 9792182]
8. Brust A, et al. omega-Conotoxins GVIA, MVIIA and CVID: SAR and clinical potential. Toxins (Basel). 2009;1(1):35-87. [PMID: PMC3397437]
9. Sather WA. Role of basic residues in omega-conotoxin GVIA binding. J Gen Physiol. 1993;102(4):745-768. [PMID: 8394704]
10. Garibaldi M, et al. Structure of human CaV2.2 channel blocked by the painkiller ziconotide. Science. 2021;373(6559):1130-1135. [PMID: 34234349]
11. Staats PS, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. JAMA. 2004;291(1):63-70. [PMID: 14709577]
12. Lubbers NL, et al. Ziconotide neurological calcium channel blocker for treating severe chronic pain. Curr Opin Investig Drugs. 2005;6(1):63-67. [PMID: 15578997]
---
For research purposes only. Peptides.SO research profiles are intended to assist laboratory scientists in understanding the pharmacology of research-grade peptide reagents. All compounds described are for in vitro and preclinical laboratory research applications only.